Flamel signs pharma supply agreement

Dec. 21, 2004 — Flamel Technologies S.A. (Nasdaq: FLML) announced today that Flamel and Glaxo-Smith Kline have signed an agreement whereby Flamel will supply GSK with commercial supplies of Flamel’s Micropump formulation of a currently marketed GSK drug. The drug was not named.

The Micropump technology was originally licensed to GSK for the drug in March 2003. Flamel’s president, Gerard Soula, said in a prepared statement that the new equipment purchased for the project will be installed in the company’s facility in Pessac, France. Cash outlays for the equipment purchases are to be underwritten by the GSK agreement.

Flamel’s Micropump is a polymer-based controlled release technology for the oral administration of small molecule drugs.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.